| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Estriol 16α-(β-D-glucuronide) primarily targets estrogen receptors and metabolic enzymes involved in steroid hormone processing; it serves as a biomarker for fetal-placental unit function and is used in radioimmunoassays for monitoring pregnancy status.
|
|---|---|
| ln Vitro |
Endogenous metabolites are those that the Kyoto Encyclopedia of Genes and Genomes has identified as products or substrates of the approximately 1900 metabolic enzymes that are encoded in human genome. Numerous of these metabolites have been shown to have harmful effects, as evidenced by the body of literature [1].
In vitro, this compound is employed as a standard and tracer in immunoassays; it exhibits binding affinity to anti-estriol antibodies and is used to quantify estriol levels in biological samples such as serum and urine, with established protocols for radioimmunoassay suitable applications. |
| ln Vivo |
In vivo, Estriol 16α-(β-D-glucuronide) reflects the metabolic conjugation and excretion of estriol; its levels in maternal urine and plasma are monitored to assess fetal well-being and placental function during pregnancy, serving as a non-invasive marker of fetal adrenal and hepatic activity.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays typically involve radioimmunoassay (RIA) procedures: the compound is incubated with specific anti-estriol antibodies and a labeled tracer (e.g., ³H-estriol) in buffer systems; bound and free fractions are separated using dextran-coated charcoal or secondary antibody precipitation; radioactivity is measured by liquid scintillation counting to generate standard curves.
|
| Cell Assay |
Cellular assays are generally not performed with this metabolite as it is used as an analytical standard; however, in cell-based studies of estrogen metabolism, the compound may be applied to cultured placental or hepatic cells to investigate glucuronidation and transport processes, with quantification via LC-MS/MS or immunoassay.
|
| Animal Protocol |
In vivo animal experiments are not typically conducted with this compound as a test substance; however, in pharmacokinetic or metabolic studies, it may be administered to pregnant animal models (e.g., rats or sheep) to study placental transfer, fetal metabolism, and urinary excretion patterns of estrogen conjugates.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties: Estriol 16α-(β-D-glucuronide) is a water-soluble conjugated metabolite with high polarity; it is primarily excreted in urine with a short half-life; its levels reflect the dynamic balance of estriol production, conjugation in the liver and placenta, and renal clearance.
|
| Toxicity/Toxicokinetics |
Toxicological profile: As an endogenous metabolite, Estriol 16α-(β-D-glucuronide) is not considered toxic at physiological concentrations; no significant adverse effects have been reported for its use as a research reagent; standard laboratory safety precautions apply when handling the compound.
|
| References |
|
| Additional Infomation |
Estriol 16-O-(β-D-glucuronide) is a steroidal glycosidic acid, a product of estriol in which the phenolic hydroxyl hydrogen is replaced by a β-D-glucuronic acid residue. It is a metabolite in human urine. It is a steroidal glycosidic acid, β-D-glucuronic acid, 3-hydroxysteroid, phenolic compound, and 17β-hydroxysteroid. Functionally, it is related to estriol. It is the conjugate acid of estriol 16-O-(β-D-glucuronide)(1-).
Other information: This compound is a reference standard for clinical diagnostics and pregnancy monitoring; it is suitable for techniques such as radioimmunoassay and LC-MS/MS; its molecular weight is 464.51 and purity is typically ≥97%. |
| Molecular Formula |
C24H32O9
|
|---|---|
| Molecular Weight |
464.51
|
| Exact Mass |
464.205
|
| CAS # |
1852-50-2
|
| PubChem CID |
122281
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.51g/cm3
|
| Boiling Point |
738.3ºC at 760mmHg
|
| Flash Point |
253.5ºC
|
| Vapour Pressure |
6.95E-23mmHg at 25°C
|
| Index of Refraction |
1.667
|
| LogP |
0.496
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
33
|
| Complexity |
747
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)CCC5=C3C=CC(=C5)O
|
| InChi Key |
FQYGGFDZJFIDPU-JRSYHJKYSA-N
|
| InChi Code |
InChI=1S/C24H32O9/c1-24-7-6-13-12-5-3-11(25)8-10(12)2-4-14(13)15(24)9-16(21(24)29)32-23-19(28)17(26)18(27)20(33-23)22(30)31/h3,5,8,13-21,23,25-29H,2,4,6-7,9H2,1H3,(H,30,31)/t13-,14-,15+,16-,17+,18+,19-,20+,21+,23-,24+/m1/s1
|
| Chemical Name |
(2S,3S,4S,5R,6R)-6-[[(8R,9S,13S,14S,16R,17R)-3,17-dihydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-16-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1528 mL | 10.7640 mL | 21.5281 mL | |
| 5 mM | 0.4306 mL | 2.1528 mL | 4.3056 mL | |
| 10 mM | 0.2153 mL | 1.0764 mL | 2.1528 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
